Verastem (VSTM) News Today $3.96 -0.23 (-5.49%) (As of 05:27 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period HC Wainwright Reaffirms Buy Rating for Verastem (NASDAQ:VSTM)December 22 at 3:11 AM | americanbankingnews.comVerastem (NASDAQ:VSTM) Price Target Raised to $9.00December 21 at 3:17 AM | americanbankingnews.comVerastem director Robert Gagnon sells $1,862 in stockDecember 20 at 4:49 PM | investing.comVerastem director Brian Stuglik sells $4,160 in stockDecember 20 at 4:49 PM | investing.comVerastem price target raised to $9 from $7 at MizuhoDecember 20 at 11:09 AM | markets.businessinsider.comVerastem (NASDAQ:VSTM) Given New $9.00 Price Target at MizuhoMizuho increased their price target on Verastem from $7.00 to $9.00 and gave the company an "outperform" rating in a research report on Thursday.December 19, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Verastem (NASDAQ:VSTM)HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Verastem in a report on Thursday.December 19, 2024 | marketbeat.comVerastem announces preliminary avutometinib and sotorasib dataDecember 18, 2024 | markets.businessinsider.comMizuho Securities Keeps Their Buy Rating on Verastem (VSTM)December 18, 2024 | markets.businessinsider.comVerastem Oncology's Triplet Combination Shows No Dose-Limiting Toxicities In RAMP 203 TrialDecember 18, 2024 | markets.businessinsider.comVerastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung CancerDecember 18, 2024 | businesswire.comVerastem (NASDAQ:VSTM) Stock Crosses Above 200 Day Moving Average - Here's WhyVerastem (NASDAQ:VSTM) Share Price Passes Above 200-Day Moving Average - What's Next?December 18, 2024 | marketbeat.comVerastem’s Promising Drug Combination for LGSOC: Analyst Recommends Buy RatingDecember 17, 2024 | markets.businessinsider.comAnalysts Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $12.50December 13, 2024 | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Given Average Rating of "Buy" by AnalystsVerastem, Inc. (NASDAQ:VSTM - Get Free Report) has earned a consensus rating of "Buy" from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analyDecember 10, 2024 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Stock Position Raised by Walleye Capital LLCWalleye Capital LLC lifted its stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 493.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 216,126 shares of the biopharmaceuticalDecember 8, 2024 | marketbeat.comVerastem: Preparing For Upcoming CatalystsNovember 27, 2024 | seekingalpha.comVerastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNovember 26, 2024 | businesswire.comVerastem Inc. Reports Increased Operating Expenses and Net LossNovember 22, 2024 | markets.businessinsider.comB. Riley Forecasts Verastem's FY2024 Earnings (NASDAQ:VSTM)Verastem, Inc. (NASDAQ:VSTM - Free Report) - Stock analysts at B. Riley increased their FY2024 earnings per share estimates for shares of Verastem in a report issued on Monday, November 18th. B. Riley analyst K. Patel now anticipates that the biopharmaceutical company will post earnings per shareNovember 21, 2024 | marketbeat.comOrbiMed Advisors LLC's Strategic Acquisition of Verastem Inc SharesNovember 15, 2024 | gurufocus.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from AnalystsShares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have earned an average recommendation of "Buy" from the eight analysts that are covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average twelve-month price target among broNovember 15, 2024 | marketbeat.comVerastem price target lowered to $14 from $20 at Alliance Global PartnersNovember 7, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Verastem (VSTM)November 7, 2024 | markets.businessinsider.comVerastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesNovember 6, 2024 | businesswire.comStrategic Advancements and Market Opportunities Propel Verastem’s Buy RatingNovember 5, 2024 | markets.businessinsider.comOptimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem’s Avutometinib and DefactinibOctober 22, 2024 | markets.businessinsider.comVerastem (NASDAQ:VSTM) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comVerastem’s Promising Advancements in LGSOC Treatment Drive Buy Rating with $7 TargetOctober 19, 2024 | markets.businessinsider.comVerastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial PotentialOctober 18, 2024 | markets.businessinsider.comRoyal Bank of Canada Reaffirms "Outperform" Rating for Verastem (NASDAQ:VSTM)Royal Bank of Canada reaffirmed an "outperform" rating and issued a $13.00 target price on shares of Verastem in a research report on Friday.October 18, 2024 | marketbeat.comVerastem (NASDAQ:VSTM) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Verastem in a research note on Friday.October 18, 2024 | marketbeat.comVerastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual MeetingOctober 17, 2024 | businesswire.comVerastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual MeetingOctober 9, 2024 | businesswire.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2024 | businesswire.comGuggenheim Initiates Coverage of Verastem (VSTM) with Buy RecommendationOctober 1, 2024 | msn.comNantahala Capital Management LLC Purchases Shares of 400,000 Verastem, Inc. (NASDAQ:VSTM)Nantahala Capital Management LLC acquired a new position in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 400,000 shares of the biopharmaceutical company's stockOctober 1, 2024 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Given Average Recommendation of "Buy" by AnalystsVerastem, Inc. (NASDAQ:VSTM - Get Free Report) has earned a consensus rating of "Buy" from the six research firms that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analystsSeptember 26, 2024 | marketbeat.comVerastem Oncology to Present at the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | businesswire.comVerastem's Path To FDA Approval: High-Risk, High-Reward Oncology OpportunitySeptember 6, 2024 | seekingalpha.comVerastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024September 3, 2024 | financialpost.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Rating of "Buy" from AnalystsShares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objectSeptember 1, 2024 | marketbeat.comOutperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation OpportunityAugust 22, 2024 | markets.businessinsider.comVerastem, Inc. (NASDAQ:VSTM) Short Interest Down 18.9% in JulyVerastem, Inc. (NASDAQ:VSTM - Get Free Report) was the target of a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 1,840,000 shares, a drop of 18.9% from the July 15th total of 2,270,000 shares. Currently, 5.9% of the company's shares are sold short. Based on an average daily trading volume, of 1,020,000 shares, the short-interest ratio is presently 1.8 days.August 15, 2024 | marketbeat.comVerastem (NASDAQ:VSTM) Given New $15.00 Price Target at Truist FinancialTruist Financial decreased their price objective on shares of Verastem from $18.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday.August 13, 2024 | marketbeat.comVerastem (NASDAQ:VSTM) Raised to "Hold" at StockNews.comStockNews.com upgraded Verastem from a "sell" rating to a "hold" rating in a report on Monday.August 12, 2024 | marketbeat.comHC Wainwright Cuts Verastem (NASDAQ:VSTM) Price Target to $7.00HC Wainwright lowered their price target on Verastem from $17.50 to $7.00 and set a "buy" rating on the stock in a research report on Monday.August 12, 2024 | marketbeat.comBuy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel OptimismAugust 12, 2024 | markets.businessinsider.comVerastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business UpdatesAugust 9, 2024 | finance.yahoo.comBuy Rating Justified by Verastem’s Promising LGSOC Drug Prospects and Strong Market PositionAugust 9, 2024 | markets.businessinsider.com Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Forced out of retirement by these trades (Ad)You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed Make sure to check out Gamma Pockets HERE while it’s still widely available VSTM Media Mentions By Week VSTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼0.000.59▲Average Medical News Sentiment VSTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼193▲VSTM Articles Average Week Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sangamo Therapeutics News Emergent BioSolutions News Codexis News XOMA News Rigel Pharmaceuticals News Vanda Pharmaceuticals News Lexicon Pharmaceuticals News Achieve Life Sciences News Regulus Therapeutics News Agenus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.